These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 34469333)

  • 1. Florid Foreign Body-type Giant Cell Response to Keratin Is Associated With Improved Overall Survival in Patients Receiving Preoperative Therapy for Esophageal Squamous Cell Carcinoma.
    Chen W; Zhao L; Agoston A; White A; Mazzola E; Boyle PJ; Deshpande V; Hornick JL; Bueno R; Bass AJ; Enzinger P; Mamon H; Redston M; Patil DT
    Am J Surg Pathol; 2021 Dec; 45(12):1648-1660. PubMed ID: 34469333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
    Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
    Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS.
    Andreollo NA; Beraldo GC; Alves IPF; Tercioti-Junior V; Ferrer JAP; Coelho-Neto JS; Lopes LR
    Arq Bras Cir Dig; 2018 Dec; 31(4):e1405. PubMed ID: 30539980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Tang H; Jiang D; Zhang S; Zeng Z; Tan L; Hou Y; Wang Q; ; Wang H; Zhu J; Shen Y; Yin J; Ge D
    J Thorac Cardiovasc Surg; 2021 Dec; 162(6):1632-1641. PubMed ID: 33268125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities.
    Deng W; Yang Z; Dong X; Yu R; Wang W
    Cancer Med; 2021 Jan; 10(2):659-674. PubMed ID: 33314798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Neoadjuvant Therapy on Poor Long-Term Outcomes of Postoperative Complications in Patients with Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study.
    Takeuchi M; Kawakubo H; Mayanagi S; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2019 Jul; 26(7):2081-2089. PubMed ID: 30937664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
    Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
    Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
    [No Abstract]   [Full Text] [Related]  

  • 8. Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer?
    Ilson D; Lordick F
    Lancet Oncol; 2018 Oct; 19(10):1285-1286. PubMed ID: 30528077
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
    Groth SS; Burt BM; Farjah F; Smaglo BG; Sada YH; Sugarbaker DJ; Massarweh NN
    J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1682-1693.e1. PubMed ID: 30711279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
    Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
    Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
    Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma.
    Miyata H; Sugimura K; Motoori M; Omori T; Yamamoto K; Yanagimoto Y; Shinno N; Yasui M; Takahashi H; Wada H; Ohue M; Yano M
    Ann Surg Oncol; 2019 Dec; 26(13):4737-4743. PubMed ID: 31414291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
    Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
    JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for recurrence of esophageal squamous cell carcinoma after pathological complete response to neoadjuvant therapy followed by esophagectomy.
    Hirohata R; Hamai Y; Emi M; Ibuki Y; Kurokawa T; Ohsawa M; Kitasaki N; Okada M
    World J Surg; 2024 Jul; 48(7):1700-1709. PubMed ID: 38757868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGF2BP3 Expression Correlates With Poor Prognosis in Esophageal Squamous Cell Carcinoma.
    Wakita A; Motoyama S; Sato Y; Nagaki Y; Fujita H; Terata K; Imai K; Maeda E; Minamiya Y
    J Surg Res; 2021 Mar; 259():137-144. PubMed ID: 33279839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prechemotherapy neutrophil : lymphocyte ratio is superior to the platelet : lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy.
    Ji WH; Jiang YH; Ji YL; Li B; Mao WM
    Dis Esophagus; 2016 Jul; 29(5):403-11. PubMed ID: 25625421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Intraoperative Opioid Use on Recurrence-Free and Overall Survival in Patients With Esophageal Adenocarcinoma and Squamous Cell Carcinoma.
    Du KN; Feng L; Newhouse A; Mehta J; Lasala J; Mena GE; Hofstetter WL; Cata JP
    Anesth Analg; 2018 Jul; 127(1):210-216. PubMed ID: 29757780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
    Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
    BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival.
    Samson P; Puri V; Lockhart AC; Robinson C; Broderick S; Patterson GA; Meyers B; Crabtree T
    J Thorac Cardiovasc Surg; 2018 Oct; 156(4):1725-1735. PubMed ID: 30054137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.